Safe Use of Right Lobe Live Donor Livers With up to 20% Macrovesicular Steatosis Without Compromising Donor Safety and Recipient Outcome

被引:21
作者
Bhangui, Prashant [1 ]
Sah, Jayant [1 ]
Choudhary, Narendra [2 ]
Gautam, Dheeraj [3 ]
Gupta, Vikas [1 ]
Srinivasan, Thiagrajan [1 ]
Rastogi, Amit [1 ]
Piplani, Tarun [4 ]
Saraf, Neeraj [2 ]
Saigal, Sanjiv [2 ]
Soin, Avi [1 ]
机构
[1] Medanta The Medicity, Medanta Inst Liver Transplantat & Regenerat Med, Delhi NCR, Delhi 122001, India
[2] Medanta The Medicity, Dept Hepatol, Medanta Inst Liver Transplantat & Regenerat Med, Delhi, India
[3] Medanta The Medicity, Dept Pathol, Delhi NCR, Delhi, India
[4] Medanta The Medicity, Dept Radiodiag, Delhi NCR, Delhi, India
关键词
FOR-SIZE SYNDROME; HEPATIC STEATOSIS; GRAFT STEATOSIS; TRANSPLANTATION; RISK; COMPLICATIONS; DEFINITION; REVERSAL;
D O I
10.1097/TP.0000000000002847
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The principle in right lobe living donor liver transplantation is to use "near-perfect" grafts to maximize recipient benefit with minimal donor risk. Whether and what degree of graft macrovesicular steatosis is safe for both recipient and donor is debatable. Methods. We compared donor and recipient outcomes in 623 primary right lobe living donor liver transplantations, using grafts with (Group A; 10%-20% steatosis, n = 92) and without (Group B; <10%, n = 531) significant macrovesicular steatosis, on pre- or intraoperative biopsy. Results. Group A donors had higher body mass index, transaminases, fasting blood sugar, triglyceride, low density lipoprotein level, and lower high density lipoprotein, and liver attenuation index on CT scan, and similar future liver remnant. Mean postoperative day (POD) 7, aspartate aminotransferase (61.13 + 24.77 vs 73.17 + 53.71 IU/L; P = 0.04), and prothrombin time-international normalized ratio (1.16 + 0.36 vs 1.28 + 0.24; P = 0.0001) were lower in Group A donors. POD3 of 7 total bilirubin and alanine aminotransferase; POD3 aspartate aminotransferase and prothrombin time-international normalized ratio; postoperative morbidity (Dindo-Clavien >3b), hospital stay were similar in both groups. Recipients in both groups had similar age, model for end-stage liver disease score. Right lobe graft weight (764.8 + 145.46 vs 703.24 + 125.53 grams; P < 0.0001) and GRWR (1.09 + 0.29 vs 1.00 + 0.21; P = 0.0004) were higher in Group A. All biochemical parameters at POD 3 of 7, as well as hospital stay, 30-day mortality were similar in recipients of both groups, even after matching both groups for age, model for end-stage liver disease, and GRWR. Conclusions. Use of well-selected right lobe grafts (adequate future liver remnant in donor, GRWR in recipient), with up to 20% macrovesicular steatosis, does not compromise graft function and outcomes and is safe for the donor.
引用
收藏
页码:308 / 316
页数:9
相关论文
共 29 条
[1]   Short- and Long-term Donor Morbidity in Right Lobe Living Donor Liver Transplantation: 91 Consecutive Cases in a European Center [J].
Azoulay, D. ;
Bhangui, P. ;
Andreani, P. ;
Salloum, C. ;
Karam, V. ;
Hoti, E. ;
Pascal, G. ;
Adam, R. ;
Samuel, D. ;
Ichai, Ph. ;
Saliba, F. ;
Castaing, D. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (01) :101-110
[2]   Improvement in survival associated with adult-to-adult living donor liver transplantation [J].
Berg, Carl L. ;
Gillespie, Brenda W. ;
Merion, Robert M. ;
Brown, Robert S., Jr. ;
Abecassis, Michael M. ;
Trotter, James F. ;
Fisher, Robert A. ;
Freise, Chris E. ;
Ghobrial, R. Mark ;
Shaked, Abraham ;
Fair, Jeffrey H. ;
Everhart, James E. .
GASTROENTEROLOGY, 2007, 133 (06) :1806-1813
[3]   Surgical assessment of significant steatosis in donor livers: The beginning of the end for frozen-section analysis? [J].
Brunt, Elizabeth M. .
LIVER TRANSPLANTATION, 2013, 19 (04) :360-361
[4]   Donor Livers with Steatosis Are Safe To Use in Hepatitis C Virus-Positive Recipients [J].
Burra, Patrizia ;
Loreno, Massimiliano ;
Russo, Francesco Paolo ;
Germani, Giacomo ;
Galligioni, Alessandra ;
Senzolo, Marco ;
Cillo, Umberto ;
Zanus, Giacomo ;
Fagiuoli, Stefano ;
Rugge, Massimo .
LIVER TRANSPLANTATION, 2009, 15 (06) :619-628
[5]   Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm [J].
Chavin, Kenneth D. ;
Taber, David J. ;
Norcross, Melissa ;
Pilch, Nicole A. ;
Crego, Heather ;
McGillicuddy, John W. ;
Bratton, Charles F. ;
Lin, Angello ;
Baliga, Prabhakar K. .
CLINICAL TRANSPLANTATION, 2013, 27 (05) :732-741
[6]   Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors [J].
Choudhary, Narendra S. ;
Saraf, Neeraj ;
Saigal, Sanjiv ;
Gautam, Dheeraj ;
Lipi, Lipika ;
Rastogi, Amit ;
Goja, Sanjay ;
Menon, Palat B. ;
Bhangui, Prashant ;
Ramchandra, Sumana K. ;
Soin, Arvinder S. .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 5 (02) :123-126
[7]   Donor Hepatic Steatosis and Outcome After Liver Transplantation: a Systematic Review [J].
Chu, Michael J. J. ;
Dare, Anna J. ;
Phillips, Anthony R. J. ;
Bartlett, Adam S. J. R. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2015, 19 (09) :1713-1724
[8]   Small-for-size syndrome after partial liver transplantation: Definition, mechanisms of disease and clinical implications [J].
Dahm, F ;
Georgiev, P ;
Clavien, PA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (11) :2605-2610
[9]   Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index [J].
de Graaf, Esther L. ;
Kench, James ;
Dilworth, Pamela ;
Shackel, Nicholas A. ;
Strasser, Simone I. ;
Joseph, David ;
Pleass, Henry ;
Crawford, Michael ;
McCaughan, Geoff W. ;
Verran, Deborah J. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (03) :540-546
[10]   Hepatic steatosis is not always a contraindication for cadaveric liver transplantation [J].
Deroose, Jan P. ;
Kazemier, Geert ;
Zondervan, Pieter ;
IJzermans, Jan N. M. ;
Metselaar, Herold J. ;
Alwayn, Ian P. J. .
HPB, 2011, 13 (06) :417-425